Cash Flow Statement

Amortization Amortization Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Receivables Change in Receivables Change in Taxes Change in Taxes Change in Working Capital Change in Working Capital Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

EBIAT Long-Term Debt Issuances Long-Term Debt Repayments Receivables - Net Receivables - Other Receivables Refunds Shares Issued Shares Outstanding Shares Outstanding

Ratios

ProQR Therapeutics (PRQR) Short-Term Debt repayments (2019 - 2022)

ProQR Therapeutics' Short-Term Debt repayments history spans 2 years, with the latest figure at -$384152.5 for Q3 2022.

On a quarterly basis, Short-Term Debt repayments rose 6.12% to -$384152.5 in Q3 2022 year-over-year; TTM through Sep 2022 was -$1.7 million, a N/A change, with the full-year FY2021 number at -$970385.7, down 1191.88% from a year prior.
Short-Term Debt repayments hit -$384152.5 in Q3 2022 for ProQR Therapeutics, down from -$380939.2 in the prior quarter.
Over the last five years, Short-Term Debt repayments for PRQR hit a ceiling of -$16859.8 in Q2 2021 and a floor of -$646466.5 in Q1 2022.